Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2012 2
2013 10
2014 20
2015 16
2016 16
2017 9
2018 7
2019 13
2020 5
2021 9
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Levomilnacipran.
[No authors listed] [No authors listed] 2024 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999699 Free Books & Documents. Review.
Levomilnacipran has not been studied in nursing mothers. However, the racemic form of milnacipran has low levels in breastmilk and would not be expected to cause any adverse effects in breastfed infants. Until more data become available, levomilnacipran should be us …
Levomilnacipran has not been studied in nursing mothers. However, the racemic form of milnacipran has low levels in breastmilk and wo …
Levomilnacipran: More of the Same?
Gautam M, Kaur M, Jagtap P, Krayem B. Gautam M, et al. Prim Care Companion CNS Disord. 2019 Sep 5;21(5):19nr02475. doi: 10.4088/PCC.19nr02475. Prim Care Companion CNS Disord. 2019. PMID: 31509357 Free article.
The evidence-based review comprises a total of 31 articles. DATA SYNTHESIS: The data analyzed suggest that levomilnacipran has evidence in the treatment of MDD. More specifically, data suggest that levomilnacipran may be unique among SSRI and SNRI antidepressants in …
The evidence-based review comprises a total of 31 articles. DATA SYNTHESIS: The data analyzed suggest that levomilnacipran has eviden …
Levomilnacipran ameliorates lipopolysaccharide-induced depression-like behaviors and suppressed the TLR4/Ras signaling pathway.
Li S, Zhu Z, Lan T, Wu Y, Li Y, Wang C, Jian W, Yu SY. Li S, et al. Int Immunopharmacol. 2023 Sep;122:110595. doi: 10.1016/j.intimp.2023.110595. Epub 2023 Jul 4. Int Immunopharmacol. 2023. PMID: 37413934 Free article.
Levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, has been reported to have anti-depressive effects. ...Furthermore, we found that levomilnacipran could decrease the number of microglia and suppress its activation in prefrontal cortex of rats. ...
Levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, has been reported to have anti-depressive effects. ...Furthermore …
LEVOMILNACIPRAN--A SUCCESSOR OF MILNACIPRAN WITH A HIGHER NORADRENERGIC SELECTIVITY.
Zadka Ł, Dziwota E, Olajossy M. Zadka Ł, et al. Acta Pol Pharm. 2016 Mar-Apr;73(2):285-9. Acta Pol Pharm. 2016. PMID: 27180420 Review.
Clinical trials have confirmed the effectiveness of levomilnacipran in the treatment of depression. The drug was placed on the US market in the form of prolonged-release capsules, which greatly simplifies the treatment of psychiatric patients. ...In this paper we present c …
Clinical trials have confirmed the effectiveness of levomilnacipran in the treatment of depression. The drug was placed on the US mar …
Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
Scott LJ. Scott LJ. CNS Drugs. 2014 Nov;28(11):1071-82. doi: 10.1007/s40263-014-0203-1. CNS Drugs. 2014. PMID: 25270036 Review.
The efficacy of levomilnacipran ER was maintained during the extension study, with no new safety signals detected; ongoing postmarketing evidence should more fully define the long-term safety of levomilnacipran ER. ...In the meantime, it is a useful addition to phar …
The efficacy of levomilnacipran ER was maintained during the extension study, with no new safety signals detected; ongoing postmarket …
Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
Palmer EC, Binns LN, Carey H. Palmer EC, et al. Ann Pharmacother. 2014 Aug;48(8):1030-1039. doi: 10.1177/1060028014535074. Epub 2014 May 8. Ann Pharmacother. 2014. PMID: 24811398 Review.
OBJECTIVE: To provide a clinical overview of the antidepressant levomilnacipran. DATA SOURCES: Articles were identified by searching the MEDLINE, PubMed, Cochrane Library, and Clinicaltrials.gov databases through March 2014 using the keyword levomilnacipran. ...Effi …
OBJECTIVE: To provide a clinical overview of the antidepressant levomilnacipran. DATA SOURCES: Articles were identified by searching …
Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
Mago R, Mahajan R, Thase ME. Mago R, et al. Expert Rev Clin Pharmacol. 2014 Mar;7(2):137-45. doi: 10.1586/17512433.2014.889563. Expert Rev Clin Pharmacol. 2014. PMID: 24524592 Review.
Levomilnacipran is a novel serotonin and norepinephrine reuptake inhibitor (SNRI) for the treatment of major depressive disorder. ...In four of the six short-term clinical trials, levomilnacipran was statistically significantly more efficacious than placebo. ...
Levomilnacipran is a novel serotonin and norepinephrine reuptake inhibitor (SNRI) for the treatment of major depressive disorder. ... …
Levomilnacipran Improves Lipopolysaccharide-Induced Dysregulation of Synaptic Plasticity and Depression-Like Behaviors via Activating BDNF/TrkB Mediated PI3K/Akt/mTOR Signaling Pathway.
Wu Y, Zhu Z, Lan T, Li S, Li Y, Wang C, Feng Y, Mao X, Yu S. Wu Y, et al. Mol Neurobiol. 2023 Dec 7. doi: 10.1007/s12035-023-03832-8. Online ahead of print. Mol Neurobiol. 2023. PMID: 38057644
Taken together, these results suggest that levomilnacipran may exert antidepressant effects via upregulating BDNF/TrkB mediated PI3K/Akt/mTOR signaling pathway to improve synaptic plasticity. These findings reveal potential mechanisms for the antidepressant effects of l …
Taken together, these results suggest that levomilnacipran may exert antidepressant effects via upregulating BDNF/TrkB mediated PI3K/ …
Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L. Citrome L. Int J Clin Pract. 2013 Nov;67(11):1089-104. doi: 10.1111/ijcp.12298. Epub 2013 Sep 8. Int J Clin Pract. 2013. PMID: 24016209 Free article. Review.
OBJECTIVE: To describe the efficacy and safety of levomilnacipran (extended-release capsules) for the treatment of major depressive disorder (MDD). ...CONCLUSIONS: Levomilnacipran represents another option for the treatment of MDD. Levomilnacipran appears to …
OBJECTIVE: To describe the efficacy and safety of levomilnacipran (extended-release capsules) for the treatment of major depressive d …
104 results